Faculty

• University of Washington
• UW Box 358070
• fax:206-732-6167

Geoffrey S. Gottlieb, MD, PhD

• Associate Professor of Medicine
• University of Washington

Dr. Gottlieb is the PI of a study in Senegal, West Africa on the effect of antiretroviral therapy (ART) on HIV-2 disease outcomes, emergence of drug resistance, and genital shedding. HIV-2 is intrinsically resistant to the non-nucleoside reverse transcriptase inhibitors (NNRTI), Fusion inhibitors (enfurvirtide), partially resistant to some protease inhibitors (PI) (and has a low genetic barrier to nucleoside reverse transcriptase inhibitors (NRTI) resistance), making treatment algorithms in resource-limited settings challenging.

He is also involved in understanding the differences between the natural history, clinical, immunologic and virologic aspects of HIV-1 and HIV-2 infection. HIV-2 is generally less pathogenic than HIV-1. Compared to HIV-1, HIV-2 infection is characterized by a much longer asymptomatic stage, lower plasma viral loads, slower decline in CD4 count, lower mortality rate due to AIDS, lower rates of mother to child transmission and lower rates of sexual transmission. In addition, he has been studying the effects of dual infection with HIV-1 and HIV-2 on disease outcomes and ART in Senegal. This work is an ongoing collaborative effort between the UW and the University of Dakar, Senegal, since the early 1990's. Project opportunities include both Senegal field work (in Dakar and Ziguinchor) and Seattle based lab studies.

Dr. Gottlieb a collaborator with the IeDEA-West Africa network to study HIV-2 throughout West Africa as well as the ACHIEV2E Network to Study HIV-2 in North America and Europe.

Dr. Gottlieb is also a Co-investigator in a study to understand the occurrence and outcome of infection with more than one strain of HIV-1. Dual HIV-1 infection (both Co- and Super-infection) as been associated with higher viral loads, faster rate of CD4 decline, and more rapid progression to AIDS. The "Superinfection Project" is a collaborative effort, between Jim Mullins' group at the UW and the MACS cohort, to elucidate the virologic and host factors associated with infection with more than one strain of HIV-1.

Collaborators

UW: Robert A. Smith, Stephen E. Hawes, Nancy B. Kiviat, Mary S. Campbell, Josh Herbeck, James I. Mullins.

Senegal and West Africa: Papa Salif Sow, Francois Dabis, Serge Paul Eholie, Didier Ekouevi

Selected Publications

Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis. 2009;199:1323–1326
[ PubMed Abstract ]

Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, Starling AK, Traore F, Sall F, Wong KG, Cherne SL, Anderson DJ, Dye SA, Smith RA, Mullins JI, Kiviat NB, Sow PS; University of Washington-Dakar HIV-2 Study Group. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis. 2009: 48:476–483.
[ PubMed Abstract ]

Gottlieb GS, Eholié SP, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle HC, Sow PS. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.AIDS. 2008 Oct 18;22(16):2069-72; discussion 2073-4.
[ PubMed Abstract ]

Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, Liu SL, Rademeyer C, Learn GH, Karim SS, Williamson C, Corey L, Margolick JB, Mullins JI. Dual HIV-1 infection associated with rapid disease progression. Lancet 2004; 363: 619-22.
[ PubMed Abstract ]

to top